Quite a few insiders invested in Lumos Pharma, Inc. (NASDAQ:LUMO) last year which is positive news...

Published on 24 Jul 2022 on Simply Wall St. via Yahoo Finance

Quite a few insiders invested in Lumos Pharma, Inc. (NASDAQ:LUMO) last year which is positive news...

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying, like in the case of Lumos Pharma, Inc. (NASDAQ:LUMO), it sends a favourable message to the company's shareholders.

While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

Check out our latest analysis for Lumos Pharma

Read the rest of the article

NASDAQ.LUMO price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates

Arcellx (ACLX) delivered earnings and revenue surprises of 72.55% and 32.55%, respectively, for t...

Zacks · via Yahoo Finance 14 May 2024

TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Tops Revenue Estimates

TFF Pharmaceuticals (TFFP) delivered earnings and revenue surprises of -9.09% and 35.33%,...

Zacks · via Yahoo Finance 29 Apr 2024

Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call Transcript

Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call Transcript March 7, 2024 Lumos Pharma, Inc...

Insider Monkey via Yahoo Finance 8 Mar 2024

Daniel Farb Buys 22% More Lumos Pharma Shares \

Investors who take an interest in Lumos Pharma, Inc. (NASDAQ:LUMO) should definitely note that in...

Simply Wall St. via Yahoo Finance 28 May 2023

Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2022 Earnings Call Transcript

Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2022 Earnings Call Transcript March 1, 2023 Operator: Good af...

Insider Monkey via Yahoo Finance 6 Mar 2023

Lumos Pharma Says Growth Hormone Deficiency Trial Meet Expectations

Lumos Pharma Inc (NASDAQ: LUMO) announced interim results from its Phase 2 OraGrowtH210 Trial and...

Benzinga via Yahoo Finance 14 Nov 2022

Lumos Pharma (LUMO) Reports Q3 Loss, Tops Revenue Estimates

Lumos Pharma (LUMO) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus ...

Zacks via Yahoo Finance 14 Nov 2022

Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates

Lumos Pharma (LUMO) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus ...

Zacks via Yahoo Finance 10 Aug 2022

Lumos Pharma (LUMO) Expected to Beat Earnings Estimates: Should You Buy?

Lumos Pharma (LUMO) is expected to deliver a year-over-year increase in earnings on higher revenu...

Zacks via Yahoo Finance 2 Aug 2022

Quite a few insiders invested in Lumos Pharma, Inc. (NASDAQ:LUMO) last year which is positive news...

Generally, when a single insider buys stock, it is usually not a big deal. However, when several ...

Simply Wall St. via Yahoo Finance 24 Jul 2022

News

Quite a few insiders invested in Lumos Pharma, Inc. (NASDAQ:LUMO) last year which is positive news...

NASDAQ.LUMO price evolution

Want to become a better investor?